The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chekhonin E.S.

National Medical and Surgical Center named after N.I. Pirogov

Fayzrakhmanov R.R.

Pirogov National Medical and Surgical Center

Sukhanova A.V.

Pirogov National Medical and Surgical Center

Bosov E.D.

National Medical and Surgical Center named after N.I. Pirogov

Anti-VEGF therapy for diabetic retinopathy

Authors:

Chekhonin E.S., Fayzrakhmanov R.R., Sukhanova A.V., Bosov E.D.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(4): 136‑142

DOI: 10.17116/oftalma2021137041136

Read: 3866 times

Download PDF (RU)
Contact the author
Table of contents

ANTI-VEGF THERAPY FOR DIABETIC RETINOPATHY
ANTI-VEGF THERAPY FOR DIABETIC RETINOPATHY

To cite this article:

Chekhonin ES, Fayzrakhmanov RR, Sukhanova AV, Bosov ED. Anti-VEGF therapy for diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(4):136‑142. (In Russ.)
https://doi.org/10.17116/oftalma2021137041136

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Indi­rect comparison of anti-angiogenic agents in the treatment of diabetic macu­lar edema. Russian Annals of Ophthalmology. 2024;(6):69-79
Dual inhi­bition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macu­lar dege­neration and diabetic macu­lar edema. Russian Annals of Ophthalmology. 2024;(6):100-106
Diabetic reti­nopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151
Angiographic para­meters of the retina after various methods of membrane peeling in the treatment of diabetic macu­lopathy. Russian Annals of Ophthalmology. 2025;(1):37-44
The effect of vitrectomy on changes in mole­cular biomarker levels of the vitreous cavity in the early postoperative period in proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(2):30-36
The effe­cts of intraoperative use of angiogenesis inhi­bitors on outcomes and complication rates in the surgical treatment of proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(2):44-50
Abstract:

Diabetic retinopathy (DR) is one of the most severe complications of diabetes mellitus, its treatment involves specialists of different areas — endocrinologists, diabetes specialists, therapists, cardiologists, surgeons, anesthesiologists etc. For ophthalmologists the objective is to diagnose ocular pathological changes associated with diabetes mellitus, and to prescribe required treatment in a timely manner. Treatment methods used in DR can be divided into three main groups: laser coagulation of the retina, intravitreal injection of medications — inhibitors of the vascular endothelial growth factor (VEGF) and glucocorticoids, as well as surgical treatment. The present literature review addresses the use of anti-VEGF drugs in the therapy of DR, specifically the latest medications, the most important studies on the treatment of DR and diabetic macular edema (DME), as well as post hoc analysis of such studies, the role of these medications in the therapy of refractory DME and proliferative stage DR. The review also addresses the upcoming strategies for therapy, as well as the importance of medications in prevention of DR and DME.

Keywords:

anti-VEGF drugs
diabetic retinopathy
diabetic macular edema

Authors:

Chekhonin E.S.

National Medical and Surgical Center named after N.I. Pirogov

Fayzrakhmanov R.R.

Pirogov National Medical and Surgical Center

Sukhanova A.V.

Pirogov National Medical and Surgical Center

Bosov E.D.

National Medical and Surgical Center named after N.I. Pirogov

Received:

30.06.2021

Accepted:

07.07.2021

Close metadata

References:

  1. Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Rossiyskiy oftal’mologicheskiy zhurnal = Russian Ophthalmological Journal. 2019; 12(2):97-105. (In Russ.). https://doi.org/10.21516/2072-0076-2019-12-2-97-105
  2. Fayzrakhmanov RR. Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment. Vestnik oftal’mologii. 2018;134(6):107-115. (In Russ.). https://doi.org/10.17116/oftalma2018134061107
  3. Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164-2172.
  4. Kanda A, Noda K, Saito W, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. https://doi.org/10.1038/srep17946
  5. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744-758.  https://doi.org/10.1016/j.cell.2014.01.043
  6. Yule Xu, Ao Rong, Yanlong Bi, Wei Xu. Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. https://doi.org/10.1155/2016/2143082
  7. Tadayoni R, Sararols L, Weissgerber G. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101.  https://doi.org/10.1159/000513048
  8. Corradetti G, Corvi F, Nguyen TV, Sadda SR. Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. Ophthalmol Retina. 2020;4(8):757-759.  https://doi.org/10.1016/j.ophtha.2019.12.031
  9. Dugel PU. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99.  https://doi.org/10.1016/j.ophtha.2020.06.028
  10. Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies, May 1—7, 2021, ARVO, Poster.
  11. Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393-401.  https://doi.org/10.2147/OPTH.S128509
  12. Lipatov DV, Lyshkanets OI. Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem. Vestnik oftal’mologii. 2019;135(4):128-139. (In Russ.). https://doi.org/10.17116/oftalma2019135041128
  13. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022
  14. Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321(19): 1880-1894. https://doi.org/10.1001/jama.2019.5790
  15. Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88-97.  https://doi.org/10.1097/IAE.0000000000002110
  16. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-568.  https://doi.org/10.1001/jamaophthalmol.2017.0821
  17. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152. https://doi.org/10.1001/archophthalmol.2012.1043
  18. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367-374.  https://doi.org/10.1016/j.ophtha.2014.08.048
  19. Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.
  20. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. https://doi.org/10.1016/j.ophtha.2016.07.032
  21. Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3:1067-1075. https://doi.org/10.1016/j.oret.2019.06.005
  22. Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. https://doi.org/10.1016/j.ophtha.2019.03.040
  23. Petrachkov DV, Budzinskaya MV, Pavlov VG, Durzhinskaya MH, Khalatyan AS. Neurodegenerative biomarkers of the response to diabetic macular edema treatment. Vestnik oftal’mologii. 2020;136(4):201-206.  https://doi.org/10.17116/oftalma2020136042201
  24. MJ E. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.
  25. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636-643.  https://doi.org/10.1097/ICU.0000000000000424
  26. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18-29.  https://doi.org/10.7326/M13-0768
  27. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular-thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for center-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3): 257-269.  https://doi.org/10.1001/jamaophthalmol.2017.6565
  28. Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258-267.  https://doi.org/10.3928/23258160-20160229-09
  29. Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498
  30. Spencer DB, Protopsaltis NJ, Chao DL. New pharmacotherapies for diabetic retinopathy. Ann Eye Sci. 2018;3(43):1-13.  https://doi.org/10.21037/aes.2018.08.02
  31. Stewart MW. Future treatments of diabetic retinopathy: pharmacotherapeutic products under development. Eur Med J Diabetes. 2017;5(1):93-103. 
  32. Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594-1608. https://doi.org/10.1007/s00125-016-3974-8
  33. Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond). 2015;29(4):534-541.  https://doi.org/10.1038/eye.2014.338
  34. Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016; 36(7):1292-1297. https://doi.org/10.1097/IAE.0000000000000876
  35. Hanhart J, Chowers I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol. 2015;6(1):44-50.  https://doi.org/10.1159/000375230
  36. Ashraf M, Souka AA, ElKayal H. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases with Non-Response to Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48(3):230-236.  https://doi.org/10.3928/23258160-20170301-06
  37. Simunovic MP, Maberley DA. Anti-Vascular Endothelial Growth Factor Therapy for Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Retina. 2015;35(10):1931-1942. https://doi.org/10.1097/IAE.0000000000000723
  38. Gross JG, Glassman AR, Jampol LM, et al; Writing Committee for the Diabetic Retinopathy Clinical Research N. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137-2146. https://doi.org/10.1001/jama.2015.15217
  39. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138-1148. https://doi.org/10.1001/jamaophthalmol.2018.3255
  40. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.  https://doi.org/10.1016/j.ophtha.2011.01.031
  41. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405. https://doi.org/10.2337/dc10-0493
  42. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5
  43. Gonzalez VH, Wang PW, Ruiz CQ. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not «1 and Done». Ophthalmology. 2019:S0161-6420(19)31932-3.  https://doi.org/10.1016/j.ophtha.2019.08.010
  44. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96(2):255-264.  https://doi.org/10.1016/s0161-6420(89)32923-x
  45. Hutton DW, Stein JD, Bressler NM, Jampol LM, Browning D, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. JAMA Ophthalmol. 2017;135(6):576-584.  https://doi.org/10.1001/jamaophthalmol.2017.0837
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.